Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Non-Current Deffered Revenue (2018 - 2021)

Summit Therapeutics' Non-Current Deffered Revenue history spans 4 years, with the latest figure at $365000.0 for Q2 2021.

  • For Q2 2021, Non-Current Deffered Revenue changed N/A year-over-year to $365000.0; the TTM value through Jun 2021 reached $365000.0, changed N/A, while the annual FY2020 figure was $569000.0, 15.42% up from the prior year.
  • Non-Current Deffered Revenue reached $365000.0 in Q2 2021 per SMMT's latest filing, down from $383000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $36.8 million in Q1 2018 to a low of $365000.0 in Q2 2021.
  • Average Non-Current Deffered Revenue over 4 years is $5.8 million, with a median of $569000.0 recorded in 2020.
  • Peak YoY movement for Non-Current Deffered Revenue: crashed 97.1% in 2019, then rose 18.33% in 2020.
  • A 4-year view of Non-Current Deffered Revenue shows it stood at $36.8 million in 2018, then tumbled by 98.69% to $480861.1 in 2019, then grew by 18.33% to $569000.0 in 2020, then tumbled by 35.85% to $365000.0 in 2021.
  • Per Business Quant, the three most recent readings for SMMT's Non-Current Deffered Revenue are $365000.0 (Q2 2021), $383000.0 (Q1 2021), and $569000.0 (Q4 2020).